Bacopa monnieri para Attention & Focus Difficulties
C Evidencia Evidencia limitada de estudios pequeños, pero existen algunas señales positivas.Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
Conclusión
Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
Key Study Findings
Población: ADHD patients (systematic review of supplements)
Población: Healthy older adults
Población: Retracted publication - invasive ductal carcinoma
Población: None
Población: None
Población: None
Key Statistics
8
Estudios
600
Participantes
Positive
Calificación
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosificaciones de uso común
- general:
- 300-600 mg/day standardized to 50% bacosides
- memorysupport:
- 300 mg/day for minimum 8-12 weeks
Límite superior: Not established; well-tolerated up to 600 mg/day in trials
Dosificaciones estudiadas en la investigación
| Dosificación | Duración | Efecto | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | 1861 |
| Bacopa monnieri (Brahmi) | -- | Positive | -- |
| None | 72 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
Mejor momento para tomar: With meals; effects require 8-12 weeks of consistent use
Safety & Side Effects
Efectos secundarios reportados
- ⚠ Gastrointestinal discomfort (nausea, cramping, diarrhea)
- ⚠ Dry mouth
- ⚠ Fatigue in some individuals
- ⚠ Mild sedation at higher doses
Interacciones conocidas
- ● Thyroid medications (may increase thyroid hormone levels)
- ● Anticholinergic drugs (opposes cholinergic enhancement)
- ● Sedative medications (additive CNS depression)
- ● Calcium channel blockers (may enhance blood pressure lowering)
Ingesta máxima tolerable: Not established; well-tolerated up to 600 mg/day in trials
Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.
Frequently Asked Questions
Does Bacopa monnieri help with Attention & Focus Difficulties?
How much Bacopa monnieri should I take for Attention & Focus Difficulties?
Are there side effects of Bacopa monnieri?
How strong is the evidence for Bacopa monnieri and Attention & Focus Difficulties?
Related Evidence
Otros ingredientes para Attention & Focus Difficulties
Bacopa monnieri para otras condiciones
References
- [1] Shatha Al Shahab et al.. Nutrients. 2025. Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review. doi:10.3390/nu17091482 PubMed
- [2] Xueyan Feng et al.. Front Pharmacol. 2025. The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of … doi:10.3389/fphar.2025.1672171 PubMed
- [3] Sohini Roy et al.. Med Oncol. 2024. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma. doi:10.1007/s12032-024-02365-x PubMed
- [4] John E Lewis et al.. J Clin Transl Res. 2021. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. PubMed
- [5] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
- [6] Andrea Brioschi Guevara et al.. Alzheimers Res Ther. 2021. Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. doi:10.1186/s13195-021-00844-1 PubMed
- [7] Michelle D Nemetchek et al.. J Ethnopharmacol. 2017. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. doi:10.1016/j.jep.2016.07.073 PubMed
- [8] Grace M McPhee et al.. Med Hypotheses. 2016. Cognitive training and Bacopa monnieri: Evidence for a combined intervention to alleviate age associated cognitive decline. doi:10.1016/j.mehy.2016.09.002 PubMed
- [9] Ananya Sadhu et al.. Clin Drug Investig. 2014. Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product. doi:10.1007/s40261-014-0235-9 PubMed
- [10] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.